The clinical significance of miR-18a-3p in traumatic spinal cord injury and its functional role in mediating apoptosis, inflammation and oxidative stress Authors: Yingnan Li, Bin Dai, Zhijian Cheng, Meini Cen Published: 2025 ABSTRACT AbstractBackgroundTraumatic spinal cord injury (TSCI) is a traumatic disease of the central nervous system that places a heavy burden on families and society. MicroRNAs (miRNAs) are intimately related to the pathophysiological processes of TSCI. This study aimed to investigate the diagnostic performance of miR-18a-3p and its molecular mechanism in TSCI.MethodsThe 218 patients with acute spinal trauma were classified according to the ASIA criteria into a normal group (n = 68), an incomplete SCI (ISCI) group (n = 85), and a complete SCI (CSCI) group (n = 65). Serum samples from participants were used to evaluate the role of miR-18a-3p in clinical diagnosis. The levels of miR-18a-3p were detected by RT-qPCR. ROC curve analysis evaluated the diagnostic performance of miR-18a-3p for TSCI. PC12 cells, which was a cell line widely used in vitro neuronal models, were treated with 5 µg/mL LPS for 12 h to simulate an inflammatory environment. Cell viability and apoptosis were assessed via CCK-8 assays and flow cytometry. Inflammatory cytokine levels were measured by ELISA. miR-18a-3p target sites were predicted using the TargetScan database. Target relationships were validated through dual-luciferase reporter assays.ResultsCompared with the Normal group, the levels of miR-18a-3p were approximately 0.4-fold higher in ISCI patients and approximately 0.7-fold higher in CSCI patients. ROC curve analysis revealed that miR-18a-3p had good diagnostic value for TSCI. It also distinguished between ISCI and CSCI patients. Additionally, the content of miR-18a-3p in patient serum had positive correlations with inflammatory cytokines (TNF-α, IL-1β, and IL-6). DLST was a target site of miR-18a-3p. In cell models, transfection with miR-18a-3p inhibitor enhanced cell viability and the levels of SOD and GSH. Meanwhile it suppressed proliferation, inflammatory factors and MDA levels. si-DLST attenuated the effects of the miR-18a-3p inhibitor.ConclusionmiR-18a-3p may be a potential diagnostic marker for TSCI. Mechanistically, downregulated miR-18a-3p inhibits apoptosis, inflammation and oxidative stress by negatively modulating DLST, thereby mitigating the progression of TSCI.Keywords: miR-18a-3p, TSCI, Apoptosis, Inflammation, Oxidative stress Background Spinal cord injury (SCI) is classified as damage to the nervous tissue of the spinal cord, leading to a reduction or loss of sensory and/or motor function [1]. It could cause severe disability and disrupt the normal functioning of various parts of the body [2–4]. More than 15 million individuals worldwide suffer from SCI, with up to 90% of cases caused by trauma [5]. The incidence of traumatic spinal cord injury (TSCI) is higher in men than in women, and the incidence rate has risen among the elderly population [6, 7]. From a pathophysiologic perspective, TSCI involves two phases: primary mechanical injury and secondary parenchymal injury. The latter has a major impact on the final degree of neurological damage and the severity of long-term sequelae in TSCI [8]. Therefore, restraining the processes involved in secondary damage may be one of the most effective methods for preventing TSCI from worsening and promoting functional recovery. Due to the lack of curative therapies and limited potential for spontaneous recovery, TSCI injury is a critical clinical challenge [9]. Surgical decompression is the most effective clinical treatment for TSCI, which can decompress the spinal cord, prevent further compression and neurological deficits and realign the spine to restore spinal stability and patient mobility [10]. However, obstacles such as axonal regeneration and neurogenesis still hinder the recovery of neurological function after SCI [11]. This underscores the critical importance of early diagnosis with TSCI, which can provide timely and effective intervention for the disease. Recently, microRNAs (miRNAs) have demonstrated significant potential in the diagnosis and treatment of musculoskeletal disorders [12–15]. A previous study indicated that miR-204-5p exerted a protective effect against intervertebral disc degeneration, positioning it as a promising therapeutic target for future interventions [16]. miR-106a-5p had the potential to diagnose osteoporosis in postmenopausal women and exerted a protective effect in postmenopausal osteoporosis by regulating PTEN under iron accumulation conditions [17]. More importantly, miRNAs play a crucial role in the treatment of SCI by modulating processes such as neuronal regeneration, macrophage polarization, inflammatory response and apoptosis [18]. For instance, silencing miR-223-5p alleviated apoptosis and inflammation in LPS-induced PC12 cells [19]. Overexpression of miR-145a-5p suppressed M1 and promoted M2 cell polarization [20]. Furthermore, multiple miRNAs, including miR-223-5p and miR-301a-3p, were considered to be potential diagnostic markers for TSCI [19, 21]. Notably, the content of miR-18a-3p was elevated in the TSCI mouse model [22, 23]. Elevated miR-18a-3p repressed osteoblast differentiation and calcium deposition, which promoted osteoporosis [24, 25]. Therefore, we speculated that miR-18a-3p may modulate the progression of skeletal diseases. Although a previous study identified dysregulated miR-18a-3p in the TSCI model, the underlying molecular mechanisms remain unexplained. Dihydrolipoamide S-succinyltransferase (DLST) is a core component of the α-ketoglutarate dehydrogenase complex, and is closely associated with glycolysis and the tricarboxylic acid cycle [26]. It has been demonstrated that the lncRNA APCDD1L-AS1 could form a complex with DSLT in lung adenocarcinoma to accelerate the TCA cycle [27]. This indicates that DLST can serve as a target site for non-coding RNA and be regulated by it. Furthermore, a study has discovered that DLST was downregulated in rats with spinal cord injury [28], suggesting its potential involvement in post-injury pathophysiological processes. However, the relationship between DLST and miR-18a-3p required further investigation. In this study, we primarily investigated the effects of miR-18a-3p on TSCI through three experimental components. (1) Serum analysis evaluated the diagnostic efficacy of miR-18a-3p detection in clinical settings; (2) An in vitro model demonstrated the protective effects of miR-18a-3p inhibitor against apoptosis, inflammation, and oxidative stress; (3) Rescue experiments confirmed that miR-18a-3p was involved in these processes by regulating DLST. Methods Clinical samples This study received approval from the Ethics Committee of The Second Affiliated Hospital of Xi’an Jiaotong University. All subjects signed informed consent forms. Our experiment involved 218 patients hospitalized at our hospital for acute spinal trauma between January 2023 and June 2024. Inclusion criteria: (1) Patients diagnosed with spinal trauma; (2) Patients diagnosed with SCI via CT and other imaging examinations; (3) Patients with a time from injury to admission ≤ 12 h; (4) Patients had not received any medication prior to admission. Exclusion criteria: (1) History of spinal cord or cranial trauma and surgery within the past 6 months; (2) History of severe cardiovascular diseases such as myocardial infarction or arrhythmia; (3) Pregnant women; (4) Patients with malignant tumors, impaired liver or kidney function, cerebrovascular diseases, or infectious diseases. Subsequently, based on the standards published by ASIA, the 218 acute spinal trauma patients were categorized into the following three groups: normal neurological function group (ASIA-E, n = 68), incomplete SCI (ASIA-B, C and D, n = 85), and complete SCI group (ASIA-A, n = 65). To evaluate the role of miR-18a-3p in the clinical diagnosis of TSCI, we collected venous blood from patients upon admission. The serum was separated by low-temperature centrifugation and stored at -80 °C. The collected serum will subsequently be used for RT-qPCR and ELISA testing. Cell culture and processing It is well known that the PC12 cell line is widely used as an in vitro neuronal model. Therefore, we simulated the inflammatory environment following TSCI by treating PC12 cells with LPS in vitro. Undifferentiated PC12 cells were procured from the ATCC and grown in DMEM (ThermoFisher, USA) supplemented with 10% FBS (ThermoFisher, USA) and 1% penicillin/streptomycin (ThermoFisher, USA) at 37 °C and 5% CO₂. According to previous research [30], PC12 cells were exposed with different concentrations of LPS (Solarbio, China) for 12 h to mimic the inflammatory environment of TSCI. The 5 µg/mL LPS treatment group was ultimately selected as the in vitro neuronal injury model. Cell transfection miR-18a-3p mimic/inhibitor, mimic/inhibitor negative control (mimic NC/inhibitor NC), DLST siRNA (si-DLST) and siRNA negative control (si-NC) were synthesized by RiboBio. Transfected cells with 50 ng miRNA mimics/inhibitors or their negative controls or 100 nM si-DLST or si-NC using Lipofectamine 2000 (ThermoFisher, USA). RT-qPCR Total RNA was extracted using TRIzol reagent (Solarbio, China) and reverse transcribed into cDNA with PrimeScript RT reagent Kit (TaKaRa, Japan). Subsequently, qRT-PCR was performed with PowerUp SYBR Green Master Mix (ThermoFisher, USA) and primers. To ensure data reliability, each set of PCR reactions contained three technical replicates. U6 served as the internal control for miR-18a-3p; GAPDH served as the internal control for DLST. Data were processed using the 2−ΔΔCt method. CCK-8 assay Seeded PC12 cells (5 × 10³ cells/well) into a 96-well plate and culture overnight before performing the specified transfection. After 48 h post-transfection, continued treatment with LPS for 12 h. Subsequently, 10 µL of CCK-8 solution (Beyotime, China) was added, and the plate was incubated for 3 h. The optical density at 450 nm was measured. Flow cytometry According to the manufacturer’s recommendations, PC12 cells were digested with trypsin and resuspended in 100 µL binding buffer. A mixture of 5 µL FITC-Annexin V and 5 µL propidium iodide (PI; Sigma, Germany) was added to the cells, which were then incubated in the dark for 20 min. Apoptosis was measured by FACScan flow cytometer (BD Biosciences, USA). Detection of inflammatory factors and oxidative stress markers The commercial ELISA kits (ThermoFisher, USA) were designed to measure the content of TNF-α (KRC3011), IL-1β (BMS630) and IL-6 (BMS625). The reaction system followed the manufacturer’s recommendations. Total Superoxide Dismutase Assay Kit with WST-8 (S0101S; Beyotime, China), GSH and GSSG Assay Kit (S0053; Beyotime, China) and Lipid Peroxidation MDA Assay Kit (S0131M; Beyotime, China) were utilized to measure the levels of SOD, GSH and MDA. The reaction system followed the manufacturer’s recommendations. Dual-luciferase reporter assay The binding sites for miR-18a-3p and DLST were acquired using TargetScanHuman 8.0. We amplified the DLST 3’UTR fragment containing the miR-18a-3p binding site and the mutant sequence at the target site. Subsequently, it was inserted into the pmirGLO vector (Promega, USA) to establish wild-type or mutant reporter vectors (DLST-wt/DLST-mut). Co-transfected PC12 cells with DLST-wt /DLST-mut and miR-18a-3p mimic/miR-18a-3p inhibitor. After 48 h, luciferase activity was measured using the Dual-Luciferase Reporter Gene Assay Kit (RG027; Beyotime, China). Statistical analysis Data were processed using IBM SPSS Statistics 27 and GraphPad Prism 9.3.1. Each group in the cell experiment included three biological replicates. ROC curve analysis evaluated the diagnostic value of miR-18a-3p. Pearson correlation analysis assessed the association between miR-18a-3p and inflammatory factors or DLST. Qualitative data comparisons were conducted by chi-square test. Quantitative data that conformed to normal distribution were analyzed by t-test or ANOVA. Data are displayed as mean ± SD. p < 0.05 was considered statistically significant. Results Baseline characteristics of participants The baseline characteristics of 218 participants were displayed in Table 1. The t-test findings indicated no significant differences in BMI (p > 0.05) among the three groups. The chi-square test results revealed no significant differences in age and gender (p > 0.05) but significant differences in traumatic location and ASIA grade (p < 0.01). Table 1Clinical characteristics of the study populationsCharacteristicsNormal (n = 68)ISCI (n = 85)CSCI (n = 65)P valueAge (years)42.79 ± 6.5142.49 ± 7.4841.91 ± 7.220.77Gender (male, %)40 (58.82%)51 (60%)38 (58.46%)0.94BMI (kg/m2)23.02 ± 2.0823.09 ± 1.8322.74 ± 2.030.54Traumatic location (n, %)0.004Cervical cord4 (5.88%)9 (10.59%)23 (35.38%)Thoracic lumbar cord64 (94.12%)76 (89.41%)42 (64.62%)ASIA grade (n, %)< 0.001A––65 (100%)B–28 (32.94%)–C–32 (37.65%)–D–25 (29.41%)–E68 (100%)––BMI, body mass index; ISCI, incomplete spinal cord injury; CSCI, complete spinal cord injury; ASIA, American Spinal Injury Association Clinical characteristics of the study populations BMI, body mass index; ISCI, incomplete spinal cord injury; CSCI, complete spinal cord injury; ASIA, American Spinal Injury Association The diagnostic performance of miR-18a-3p and its correlation with inflammatory factors Compared with the Normal group (n = 68), the levels of miR-18a-3p were approximately 0.4-fold higher in ISCI patients (n = 85) and approximately 0.7-fold higher in CSCI patients (n = 65) (p < 0.001; Fig. 1A). ROC curve analysis revealed that miR-18a-3p had good diagnostic value for TSCI (AUC = 0.905, 95% CI: 0.862–0.947, cutoff value = 1.15, Sensitivity = 89.3%, Specificity = 79.4%). It also distinguished between ISCI and CSCI patients (AUC = 0.797, 95% CI: 0.724–0.870, cutoff value = 1.51, Sensitivity = 73.8%, Specificity = 72.9%; Fig. 1B-C). Furthermore, there was a positive correlation between miR-18a-3p and proinflammatory factors in patient serum (Fig. 1D-F). The diagnostic performance of miR-18a-3p and its correlation with inflammatory factors. (A) Compared with the Normal group (n = 68), the levels of miR-18a-3p were approximately 0.4-fold higher in ISCI patients (n = 85) and approximately 0.7-fold higher in CSCI patients (n = 65). Data are presented as mean ± SD. ***p < 0.001. (B-C) miR-18a-3p could distinguish between normal and TSCI patients (AUC = 0.905, 95% CI: 0.862–0.947, cutoff value = 1.15, Sensitivity = 89.3%, Specificity = 79.4%) or ISCI and CSCI patients (AUC = 0.797, 95% CI: 0.724–0.870, cutoff value = 1.51, Sensitivity = 73.8%, Specificity = 72.9%). (D-F) Serum miR-18a-3p was positively correlated with proinflammatory factor. The X-axis represented the relative expression of miR-18a-3p in serum samples, with values determined by qRT-PCR and normalized The effect of miR-18a-3p on cell viability and apoptosis PC12 cells were exposed to LPS to mimic the inflammatory environment following TSCI. The content of miR-18a-3p increased approximately 0.4-fold, 0.6-fold, 1.2-fold and 1.4-fold under LPS treatments of 1, 2, 5 and 10 µg/mL, respectively (p < 0.05; Fig. 2A).Additionally, introduction of the miR-18a-3p inhibitor led to a 45% reduction in endogenous miR-18a-3p expression. It diminished the miR-18a-3p level following LPS treatment (p < 0.001; Fig. 2B). Furthermore, LPS treatment repressed cell viability while enhancing apoptosis. miR-18a-3p inhibitor produced the opposite effect (p < 0.001; Fig. 2C-D). The effects of miR-18a-3p on cell viability and apoptosis. Data are presented as mean ± SD (n = 3 per group). (A) The level of miR-18a-3p was positively correlated with LPS concentration. ***p < 0.001, *p < 0.05. (B) Transfection with miR-18a-3p inhibitor reduced the miR-18a-3p levels in control and LPS-treated group. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS. (C-D) Downregulated miR-18a-3p alleviated the suppression of cell viability and promotion of apoptosis by LPS. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS The impact of miR-18a-3p on inflammation and oxidative stress ELISA results exhibited that LPS treatment significantly elevated the release of inflammatory factors. Inhibiting miR-18a-3p repressed LPS-activated inflammatory responses, as evidenced by reduced of proinflammatory factors in cells (p < 0.001; Fig. 3A-C). Regarding oxidative stress, LPS treatment reduced SOD and GSH levels while increasing MDA levels. miR-18a-3p inhibitor mitigated the effects of LPS on oxidative stress markers (p < 0.001; Fig. 3D-F). The impact of miR-18a-3p on inflammation and oxidative stress. Data are presented as mean ± SD (n = 3 per group). (A–C) Downregulated miR-18a-3p reduced the levels of inflammatory factors in LPS-treated group. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS. (D–F) Downregulated miR-18a-3p elevated SOD and GSH levels and diminished MDA levels in PC12 cells following LPS treatment. ***p < 0.001 vs. control; ###p < 0.001 vs. LPS DLST was a target site of miR-18a-3p We predicted the potential targets of miR-18a-3p with TargetScan database. The outcomes revealed that miR-18a-3p has a putative conserved target site in DLST (Fig. 4A). In the DLST-wt group, the luciferase activity was depressed by miR-18a-3p mimic and boosted by miR-18a-3p inhibitor. In the DLST-mut group, no significant changes were observed (p < 0.001; Fig. 4B). Moreover, compared with the Normal group (n = 68), the DLST content decreased by 0.35-fold in ISCI patients (n = 85) and by 0.6-fold in CSCI patients (n = 65) (p < 0.001; Fig. 4C). The levels of DLST were negatively correlated with miR-18a-3p (Fig. 4D). DLST was the target site of miR-18a-3p. (A) The binding site of miR-18a-3p and DLST. (B) In the DLST-wt group, luciferase activity was depressed by miR-18a-3p mimic and boosted by miR-18a-3p inhibitor. No obvious changes were observed in the DLST-mut group. ***p < 0.001. (C) Compared with the Normal group (n = 68), the DLST content decreased by 0.35-fold in ISCI patients (n = 85) and by 0.6-fold in CSCI patients (n = 65). ***p < 0.001. (D) miR-18a-3p and DLST were significantly negatively correlated miR-18a-3p affects apoptosis, inflammation and oxidative stress via regulation of DLST Transfection outcomes demonstrated that the si-DLST knockdown efficiency was 61%. miR-18a-3p inhibitor elevated DLST levels in the LPS-treated group. Meanwhile, si-DLST mitigated the promoting effect of the miR-18a-3p inhibitor (p < 0.01; Fig. 5A). In LPS-treated PC12 cells, inhibiting miR-18a-3p enhanced cell viability and suppressed apoptosis. These effects were attenuated by silencing DLST (p < 0.01; Fig. 5B-C). Additionally the reduction in inflammatory factor levels in the LPS-treated group was rescued by downregulated DLST (p < 0.01; Fig. 5D-F). Similarly, miR-18a-3p suppression increased SOD and GSH levels while reducing MDA levels in LPS-treated PC12 cells. si-DLST attenuated the effects of the miR-18a-3p inhibitor (p < 0.05; Fig. 5G-I). miR-18a-3p regulated apoptosis, inflammation and oxidative stress by negatively modulating DLST. Data are presented as mean ± SD (n = 3 per group). (A) si-DLST reduced the DLST expression in PC12 cells. Additionally, LPS treatment reduced DLST levels. The miR-18a-3p inhibitor elevated DLST expression in the LPS-treated group. This effect was reversed by si-DLST. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS; &&p < 0.01, vs. LPS + miR-18a-3p inhibitor. (B-C) Downregulated miR-18a-3p enhanced cell viability and suppressed apoptosis in PC12 cells following LPS treatment. si-DLST attenuated these effects. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS; &&p < 0.01, vs. LPS + miR-18a-3p inhibitor. (D-F) The reduction in inflammatory factor levels in the LPS-treated group caused by the miR-18a-3p inhibitor was rescued by silenced DLST. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS; &&&p < 0.001, &&p < 0.01, vs. LPS + miR-18a-3p inhibitor. (G-I) The increased levels of SOD and GSH and reduced levels of MDA in the LPS-treated group caused by downregulation of miR-18a-3p were reversed by si-DLST. ***p < 0.001, vs. control; ###p < 0.001, vs. LPS; &&p < 0.01, &p < 0.05, vs. LPS + miR-18a-3p inhibitor Discussion TSCI is the damage to the structure and function of the spinal cord caused by various factors such as traffic accidents, falls from heights and violent injuries [31]. It is further categorized into primary and secondary injuries. Primary injury damages glial cells and neurons, triggering a series of inflammatory cascades over time [32]. Secondary injury includes oxidative stress, inflammatory response, ischemia, cell death and edema, which significantly affect the prognosis of SCI patients after surgery [33]. Thus, mitigating secondary injury is an essential goal of acute-phase intervention. The role of non-coding RNAs in musculoskeletal conditions is increasingly recognized [34–37]. They could serve as potential therapeutic agents or treatment targets for these diseases [38, 39]. Furthermore, an increasing number of miRNAs have been identified to influence secondary injury. Increasingly, miRNAs are being identified that influence secondary injury. For instance, suppressing miR-223-5p mitigated inflammation and oxidative stress in LPS-treated PC12 cells [40]. Upregulated miR-301a-3p caused diminished cell viability and elevated inflammatory factor levels in SCI cell models [21]. These miRNAs were dysregulated in TSCI patients and were considered to be potential biomarkers for TSCI diagnosis [41, 42]. In this study, comparison of clinical baseline information revealed no remarkable differences in age, gender, and BMI among patients with normal neurological function, ISCI and CSCI. However, there were significant differences in traumatic location and ASIA grade. These outcomes are in accordance with previous results, indicating that the patients enrolled in our study are representative [21]. It is notable that miR-18a-3p was elevated in ISCI and CSCI patients and could distinguish between normal and TSCI patients or ISCI and CSCI patients. This indicates that miR-18a-3p may serve as a diagnostic biomarker for TSCI. Furthermore, the content of miR-18a-3p and proinflammatory factors in patient serum was positively correlated. In conclusion, we speculated that miR-18a-3p is involved in the progression of TSCI. The elevated levels of miR-18a-3p in osteoporosis and osteoporotic vertebral fractures caught our attention [25]. Upregulated miR-18a-3p could inhibit calcium deposition and osteoblast differentiation, facilitate the progression of osteoporosis [25, 43]. Therefore, we hypothesized that miR-18a-3p is involved in the progression of skeletal diseases. Moreover, miR-18a-3p was upregulated in post-traumatic stress disorder, which is a disease associated with TSCI [23, 44]. The upregulation of miR-18a-3p in the above diseases is consistent with our outcomes. Interestingly, miR-18a-3p knockdown reduced the apoptosis in osteoarthritic mice [45], consistent with our findings. Our experiments demonstrated that downregulation of miR-18a-3p suppressed apoptosis and promoted cell viability in LPS-treated PC12 cells. Additionally, suppressing miR-18a-3p also reduced inflammatory response and oxidative stress. DLST is a cuproptosis gene. Copper death is a newly discovered form of cell death [46]. TSCI leads to disruption of the internal environment and compromise of the blood-brain barrier integrity, allowing large amounts of copper ions in the blood to flood into spinal cord tissue [28]. Simultaneously, TSCI-induced inflammatory responses and oxidative stress further disrupt the normal function of copper transporters. Copper ions induce oligomerization by binding to acylated DLAT and DLST through disulfide bonds [47]. DLAT and DLST are core components of the Pyruvate Dehydrogenase Complex (PDC) and α-Ketoglutarate Dehydrogenase Complex (KGDHC), respectively, which are essential for the TCA cycle. These alterations ultimately lead to cell death. Bioinformatics research has found downregulated DLST in a bunch of diseases, like sepsis, acute myocardial infarction and acute kidney injury [48–50]. However, there is currently minimal research on the mechanisms of DLST. Notably, the content of DLST was reduced in SCI rats [28]. Our clinical findings reached the same conclusion. We discovered that the levels of DLST were reduced in both ISCI and CSCI patients. Silencing DLST alleviated the repressive effects of downregulated miR-18a-3p on apoptosis, inflammation and oxidative stress. Hence, we hypothesized that miR-18a-3p promoted neuronal apoptosis, inflammatory response and oxidative stress by modulating DLST, thereby advancing TSCI progression. It must be acknowledged that the observed phenomenon could also result from miR-18a-3p regulation via other target sites. However, our rescue experiment results demonstrated the impact of downregulated DLST on miR-18a-3p’s inhibitory function, strongly supporting DLST’s central role in its mechanism. Several limitations should be considered when interpreting these findings. First, the sample size is small and the source is limited. Since all patients were from the surrounding areas of our hospital, the selection of samples may have unavoidable biases. In the future, we will conduct a large-scale, multi-center study to further refine the research results. Second, although the article conducted molecular mechanism studies of miR-18a-3p using cell models, there is a lack of supporting data from in vivo animal experiments. In the future, we will continue to probe the role of miR-18a-3p in animal models and conduct more comprehensive research. Moreover, our study collected blood samples at a single time point, which limits our ability to observe the dynamic changes in miR-18a-3p following TSCI. In future work, we will employ longitudinal sampling to enhance the predictive value of miR-18a-3p. Finally, using U6 as an internal control for serum-derived miRNAs carries certain risks. In subsequent work, we will employ alternative reference genes to further validate our findings. Furthermore, investigating the correlation between oxidative stress markers and miR-18a-3p in serum is also planned for future research. Conclusions Overall, miR-18a-3p may serve as a potential diagnostic biomarker for TSCI. Mechanistically, downregulated miR-18a-3p inhibits apoptosis, inflammation and oxidative stress by negatively modulating DLST, thereby mitigating the progression of TSCI. These findings provide a potential diagnostic biomarker and therapeutic targets for future TSCI treatments. Acknowledgements Not applicable. Author contributions Y.N. L. and M.N. C. designed this study. B. D. and Z.J. C. conducted the experiment. Y.N. L. and M.N. C. analyzed the data. Y.N. L. and B. D. wrote the manuscript. Z.J. C. and M.N. C. revised the manuscript. All authors reviewed and approved for publication. Funding No funding was received to assist with the preparation of this work. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of The Second Affiliated Hospital of Xi’an Jiaotong University. All subjects signed informed consent forms. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Conflict of interest Authors declare no conflict of interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.